NANOSEPSIS
Rapid Magnetic Blood Filtration for the Treatment of Sepsis: a Feasibility Study
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NANOSEPSIS project word cloud
Explore the words cloud of the NANOSEPSIS project. It provides you a very rough idea of what is the project "NANOSEPSIS" about.
Project "NANOSEPSIS" data sheet
The following table provides information about the project.
| Coordinator |
MEDISIEVE LTD
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Project website | http://www.medisieve.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2017-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MEDISIEVE LTD | UK (LONDON) | coordinator | 50˙000.00 |
Map
Project objective
This project will look at a novel method of treating sepsis, one of the world’s leading causes of death. The method uses magnetic nanoparticles (MNPs) that bind to specific entities in blood, combined with MediSieve's patented magnetic blood filter. By infusing the MNPs into an extra-corporeal blood loop containing the filter, MediSieve can remove both the pathogens that cause sepsis (bacteria) and the endotoxins that are responsible for the dysregulated immune response which is characteristic of sepsis. Importantly the method would work even in antibiotic resistant cases.
Annually, there are 1M cases in the US and 900K in Europe, with 135K deaths/year in the EU. Mortality rates are 29-50% with a cost of €25K per patient. With the aging of global populations sepsis incidence is increasing rapidly (8-13% annually in the decade to 2013).
The challenge is that both the pathogens and the immune response contribute to the disease. The destruction of bacteria by the immune system or antibiotics creates large quantities of endotoxins, which in turn aggravate the immune response and cause a cascade towards septic shock. MNPs that bind specifically to gram-negative bacteria and endotoxins enable the two targets to be rapidly and safely removed from circulation using MediSieve’s magnetic filter. The method provides the unique capability to specifically target both root causes of sepsis, reduce both the mortality and the economic costs of sepsis.
The objectives of this Phase 1 study are to validate the technical and commercial feasibility of the proposed treatment method. The latter includes detailed market research, business planning, healthcare economics modelling and a detailed investment proposal with timelines and return on investment projections. The technical assessment will include in vitro lab studies validating that the MNPs efficiently bind to both targets and captured by the magnetic filter. A Phase 2 project would include pre-clinical and clinical studies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSEPSIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NANOSEPSIS" are provided by the European Opendata Portal: CORDIS opendata.